Excretion of doxifluridine catabolites in human bile assessed by 19F NMR spectrometry.
The biliary excretion of doxifluridine (5'dFUR) catabolites was studied in a patient with external bile derivation using 19F NMR spectrometry, alpha-fluoro-beta-alanine (FBAL) and fluoride ion were detected in patient's bile samples but represented only about 10% of the excreted fluorinated metabolites. The major biliary metabolite (congruent to 90%), whose structure is still unknown, is a conjugate of FBAL. The cumulative biliary excretion of 5'dFUR fluorinated metabolites was low and represented 0.8% of the injected dose.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000970:Antineoplastic Agents / Q000378:metabolism*; D001646:Bile / Q000378:metabolism*; D003110:Colonic Neoplasms / Q000188:drug therapy; D005467:Floxuridine / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male
D000970:Antineoplastic Agents; D005467:Floxuridine; C025034:doxifluridine